Necl-4/CADM4 regulates GABAergic synaptic strength on GABAergic inhibitory neurons via ErbB4 activation and prevents neuronal impairments.

Journal: Molecular neurobiology
Published Date:

Abstract

Neural networks comprise excitatory and inhibitory neurons, linked through excitatory and inhibitory synapses. Synaptic excitation/inhibition balance is controlled for brain development and functions, and its dysregulations are implicated in aging-dependent neuronal impairments. Here, we found that Necl-4/CADM4, an immunoglobulin superfamily cell adhesion molecule, is expressed in γ-aminobutyric acidergic (GABAergic) inhibitory neurons and localizes at GABAergic synapses on inhibitory neurons in cultured hippocampal neurons and the mouse hippocampus. Necl-4 genetic ablation induced neuronal loss with synaptic degenerations in the hippocampus, and cultured Necl-4-knockout (KO) hippocampal neurons were more susceptible to death. Prior to the neuronal death, the Necl-4-KO hippocampal neurons showed an increase in GABAergic synapse density on inhibitory neurons and in synaptic molecules at GABAergic synapses on inhibitory neurons, which were regulated by ErbB4 activation. Furthermore, electrophysiological analysis revealed that Necl-4 genetic ablation enhanced GABAergic synaptic currents on inhibitory neurons and induced high-frequency firing in dissociated hippocampal cultures composed of glutamatergic excitatory neurons and inhibitory neurons, contributing to excitotoxicity-mediated neuronal death. Thus, Necl-4 regulates GABAergic synaptic strength on inhibitory neurons via ErbB4 activation and prevents neuronal impairments.

Authors

  • Ryouhei Komaki
    Division of Pathogenetic Signaling, Department of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650-0047, Japan.
  • Hajime Shiotani
    Division of Pathogenetic Signaling, Department of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650-0047, Japan.
  • Toshihiko Kuriu
    Center for Medical Research and Development, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, 569-8686, Japan.
  • Takeshi Kameyama
    Division of Pathogenetic Signaling, Department of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650-0047, Japan.
  • Muneaki Miyata
    Division of Pathogenetic Signaling, Department of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650-0047, Japan.
  • Shin Kedashiro
    Division of Pathogenetic Signaling, Department of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650-0047, Japan.
  • Kimitaka Katanazaka
    Division of Pathogenetic Signaling, Department of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650-0047, Japan.
  • Shota Nishii
    Division of Pathogenetic Signaling, Department of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650-0047, Japan.
  • Norio Chihara
    Division of Neurology, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650-0017, Japan.
  • Riki Matsumoto
    Division of Neurology, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650-0017, Japan.
  • Michinori Koebis
    Section of Animal Research and Laboratory of Animal Resources, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, 113-0033, Japan.
  • Atsu Aiba
    Section of Animal Research and Laboratory of Animal Resources, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, 113-0033, Japan.
  • Kiyohito Mizutani
    Division of Pathogenetic Signaling, Department of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650-0047, Japan. kiyohito_mizutani@tokushima-u.ac.jp.
  • Yoshimi Takai
    Division of Pathogenetic Signaling, Department of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Hyogo, 650-0047, Japan. ytakai@med.kobe-u.ac.jp.

Keywords

No keywords available for this article.